Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Proven Safety Performance at a Fraction of the Cost of Air-Assisted Devices

Nursing aides, orderlies, and attendants in hospitals and other treatment facilities are relied on to lend a helping hand daily. Concern for the safety and well-being of patients is their top priority, but this often comes at the expense of their own health. Keeping staffs healthy is critical to a hospital’s efficiency and the level…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Nursing aides, orderlies, and attendants in hospitals and other treatment facilities are relied on to lend a helping hand daily. Concern for the safety and well-being of patients is their top priority, but this often comes at the expense of their own health. Keeping staffs healthy is critical to a hospital’s efficiency and the level of care they can provide.

The Toll of Helping Out

According to the Bureau of Labor Statistics, from 1995-2004, the aforementioned occupations reported the third-highest number of injuries and illnesses. The Bureau reported that 53% of these cases were due to overexertion on the job, and 65% of these overexertion cases were attributed to patient lifting.

Back, neck and shoulder strain are common maladies experienced during the day-to-day duties of nurses and orderlies, and typically, these caregivers work non-stop with very few breaks to recover. A solution to this bodily stress is a soft rollboard. These are proven strain-relievers, especially compared to air-assisted devices. In fact, rollboards can produce as much as 15% less force than air-assisted applications.

Creating a Better Work Environment

Recently, a study was performed to better understand the dynamic biomechanical demands of a caregiver while laterally transferring a patient. To apprehend the strains on the caregivers’ lower backs and shoulders, operators performed tests using six lateral transfer assistance tools, measuring the peak force on the different areas at the 50th and 95th percentile of anthropomorphic test dummy weight to simulate average and heavier patient weights.

When compared to the other five lateral transfer solutions—incontinent pad/draw sheets, incontinent pad over slide boards, friction reducing sheets, slide boards and air-assisted devices—the rollboard was ranked the second-best tool for the lower back and the best solution for shoulders with a peak force of 154.10 Newtons.

The Right Rollboard Solution

AliMed soft rollboards employ conveyor-belt mechanics to allow for smooth patient transfers. Because no lifting is required, strain on the caregiver’s lower back and shoulders is significantly reduced. Featuring a soft core to provide comfort for patients during the transport process, both short and long board options are available, with wide options available in both lengths. All AliMed soft rollboards include handles for even easier transport, and Gold rollboards come equipped with Ultra-Fresh ionic-silver antimicrobial protection on fabric covers to prevent odors and stains.

Keeping Hospital Staffs Safe

For nearly 50 years, AliMed has been pioneering solutions that “help people help people”. As an industry leader in medical, healthcare and ergonomic products, AliMed understands that the safety and health of caregivers are paramount to the treatment of patients. As such, they are committed to developing innovative and unique healthcare products designed to help caregivers reduce the pains and aches related to their daily tasks while improving patient outcomes.

To learn more about AliMed’s soft rollboards, click here.

REFERENCES

  1. https://www.alimed.com/_resources/common/userfiles/file/LateralTransferDeviceStudy.pdf

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512